Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications

Frontiers in Medicine

Ainhoa González-Luis¹  Atteneri Pérez-Castro¹  Carmen Mora-Fernández¹  Carla M. Ferri²  Fátima Sánchez-Quintana²  Javier Donate-Correa³  Ernesto Martín-Núñez⁴  Juan F. Navarro-González⁵ 

[1]Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

[2]Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

[3]Doctoral and Graduate School, University of La Laguna, San Cristóbal de La Laguna, Spain

[4]Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

[5]GEENDIAB (Grupo Español para el Estudio de la Nefropatía Diabética), Sociedad Española de Nefrología, Santander, Spain

[6]Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

[7]GEENDIAB (Grupo Español para el Estudio de la Nefropatía Diabética), Sociedad Española de Nefrología, Santander, Spain

[8]Doctoral and Graduate School, University of La Laguna, San Cristóbal de La Laguna, Spain

[9]Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

[10]GEENDIAB (Grupo Español para el Estudio de la Nefropatía Diabética), Sociedad Española de Nefrología, Santander, Spain

[11]REDINREN (Red de Investigación Renal-RD16/0009/0022), Instituto de Salud Carlos III, Madrid, Spain

[12]Instituto de Tecnologías Biomédicas, Universidad de La Laguna, Santa Cruz de Tenerife, Spain

关键词: diabetic kidney disease;    inflammation;    inflammatory cytokines;    SGLT2i;    GLP-1RA;    DPP-4i;    pentoxifylline;   

DOI  :  10.3389/fmed.2020.628289

来源: Frontiers

【 摘 要 】

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease and a main contributing factor for cardiovascular morbidity and mortality in patients with diabetes mellitus. Strategies employed to delay the progression of this pathology focus on the control of traditional risk factors, such as hyperglycemia, and elevated blood pressure. Although the intimate mechanisms involved in the onset and progression of DKD remain incompletely understood, inflammation is currently recognized as one of the main underlying processes. Untangling the mechanisms involved in the appearing of a harmful inflammatory response in the diabetic patient is crucial for the development of new therapeutic strategies. In this review, we focus on the inflammation-related pathogenic mechanisms involved in DKD and in the therapeutic utility of new anti-inflammatory strategies.

【 授权许可】

CC BY